UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 229

Sortiert nach

Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA

European urology, 2021-03, Vol.79 (3), p.343-350

2021

Link zum Volltext

Verfügbarkeit prüfen

Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer

The Journal of urology, 2016-08, Vol.196 (2), p.382

2016

Link zum Volltext

Verfügbarkeit prüfen

Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography

European urology, 2022-08, Vol.82 (2), p.156-160

2022

Link zum Volltext

Verfügbarkeit prüfen

Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions

The Journal of nuclear medicine (1978), 2017-03, Vol.58 (3), p.445-450

2017

Link zum Volltext

Verfügbarkeit prüfen

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide

European urology, 2017-11, Vol.72 (5), p.828-834

2017

Link zum Volltext

Verfügbarkeit prüfen

Transitions between Lamellar Orientations in Shear Flow

Macromolecules, 2018-06, Vol.51 (12), p.4642-4659

2018

Link zum Volltext

Verfügbarkeit prüfen

Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy

European urology, 2021-04, Vol.79 (4), p.537-544

2021

Link zum Volltext

Verfügbarkeit prüfen

Reply to Giancarlo Marra, Armando Stabile, Paolo Gontero, Francesco Montorsi, Alberto Briganti, and Giorgio Gandaglia’s Letter to the Editor re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.11.019: A Storm in a Teacup

European urology, 2022-05, Vol.81 (5), p.e117-e117

2022

Link zum Volltext

Verfügbarkeit prüfen

EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer

Cancers, 2023-10, Vol.15 (20), p.5008

2023

Link zum Volltext

Verfügbarkeit prüfen

Positive Predictive Value and Correct Detection Rate of 18 F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard

Journal of Nuclear Medicine, 2021-07, Vol.62 (7), p.968-974

2021

Link zum Volltext

Verfügbarkeit prüfen

Topography of Lymph Node Metastases in Prostate Cancer Patients Undergoing Radical Prostatectomy and Extended Lymphadenectomy: Results of a Combined Molecular and Histopathologic Mapping Study

European urology, 2014-08, Vol.66 (2), p.222-229

2014

Link zum Volltext

Verfügbarkeit prüfen

Early Prostate-Specific Antigen Changes and Clinical Outcome After 177 Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

Journal of Nuclear Medicine, 2020-10, Vol.61 (10), p.1476-1483

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, Predictive Factors, and Prediction Nomograms for 68 Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy

European urology, 2018-05, Vol.73 (5), p.656-661

2018

Link zum Volltext

Verfügbarkeit prüfen

One-Stop-Shop Whole-Body 68 Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer

Journal of Nuclear Medicine, 2018-12, Vol.59 (12), p.1850-1856

2018

Link zum Volltext

Verfügbarkeit prüfen

Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT

European radiology, 2014-08, Vol.24 (8), p.1821-1826

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen–ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy

European urology, 2018-05, Vol.73 (5), p.656-661

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer

European urology, 2019-06, Vol.75 (6), p.920-926

2019

Link zum Volltext

Verfügbarkeit prüfen

Chromogranin A and neurone‐specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration‐resistant prostate cancer undergoing abiraterone therapy

BJU international, 2017-01, Vol.119 (1), p.30-37

2017

Link zum Volltext

Verfügbarkeit prüfen

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer

Translational andrology and urology, 2021-10, Vol.10 (10), p.3963-3971

2021

Link zum Volltext

Verfügbarkeit prüfen

99mTechnetium-based Prostate-specific Membrane Antigen–radioguided Surgery in Recurrent Prostate Cancer

European urology, 2019-04, Vol.75 (4), p.659-666

2019

Link zum Volltext

Verfügbarkeit prüfen

Extended Lymph Node Dissection for Bladder Cancer: Do Clinical Trials Rule Out a Benefit?

European urology focus, 2020-07, Vol.6 (4), p.617-619

2020

Link zum Volltext

Verfügbarkeit prüfen

Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer

Asian Journal of Urology, 2022-01, Vol.9 (1), p.69-74

2022

Link zum Volltext

Verfügbarkeit prüfen

Rational indication for docetaxel rechallenge in metastatic castration‐resistant prostate cancer

BJU international, 2012-12, Vol.110 (11b), p.E635-E640

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 229

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(188)
Mit Volltextzugriff
(201)

Publikationsform

Sprache

Englisch
(197)
Deutsch
(33)
Japanisch
(31)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial

Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer

Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography

Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide

Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen–radioguided Surgery

Transitions between Lamellar Orientations in Shear Flow

Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy

EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer

Positive Predictive Value and Correct Detection Rate of 18 F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard

Topography of Lymph Node Metastases in Prostate Cancer Patients Undergoing Radical Prostatectomy and Extended Lymphadenectomy: Results of a Combined Molecular and Histopathologic Mapping Study

Early Prostate-Specific Antigen Changes and Clinical Outcome After 177 Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

Efficacy, Predictive Factors, and Prediction Nomograms for 68 Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy

One-Stop-Shop Whole-Body 68 Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer

Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT

Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen–ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer

Chromogranin A and neurone‐specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration‐resistant prostate cancer undergoing abiraterone therapy

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer

99mTechnetium-based Prostate-specific Membrane Antigen–radioguided Surgery in Recurrent Prostate Cancer

Extended Lymph Node Dissection for Bladder Cancer: Do Clinical Trials Rule Out a Benefit?

Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer

Rational indication for docetaxel rechallenge in metastatic castration‐resistant prostate cancer

Aktive Filter

Suchergebnisse filtern